Patients who reported severe Covid-19 had small clots in their venous and arterial blood vessels – something not seen in patients with mild to moderate infections – but their skin remained normal. new research.
Research, published year American Journal of Pathology, documents that minimally invasive skin biopsy can help assess tissue damage associated with Covid-19 as well as help distinguish this vascular disease from other severe forms of respiratory disease .
“We were the first group to recognize that the acute lung disease of Covid-19 is different from other serious respiratory infections and that the unusual pathology is systemic,” explains lead author Jeffrey Laurence. Prior to this study, invasive procedures such as nerve, kidney, or lung biopsies would be required.
Researchers collected simple 4mm perforated biopsies of normal delta skin from 15 Covid patients in intensive care and six patients with mild/moderate symptoms. Biopsy samples from nine hospitalized patients with severe, critical respiratory or kidney disease who died before the pandemic era were also analyzed.
Microthrombi, or small blood clots, were detected in 87% of patients with severe infections. No microthrombi was detected in the biopsies of patients in the other two groups.
Elevated levels of an interferon-induced inflammatory protein, SIN3A – found only in the severe Covid group – are associated with the severity of the patient’s illness and may contribute to the characteristic cytokine storm in these patients. this multiplier.
“If confirmed in a longitudinal cohort, earlier identification of factors associated with severe Covid-19 using simple skin biopsies in patients in the early stages of SARS-CoV- 2 could help identify people at risk of acute disease progression and long-term COVID and allow Dr. Laurence to add.
Have your precautions? You’d best hope that the government starts to authorize a second booster shot soon.
According to one new research led by the US Centers for Disease Control and Prevention, the second booster shot significantly improved effectiveness against the common Omicron subtypes BA.1, BA.2 and BA.2.12.1.
With the first booster, the vaccine’s effectiveness against these variants was only 68% – lower than previous variants – and dropped to 52% effective after six months. As a reminder, all variants of Omicron avoid vaccine-induced immunity as well as those derived from previous infections.
With the second vaccine, effectiveness against the aforementioned subtypes increased to 80% within the first six months, adds published research in the CDC’s Morbidity and Mortality Weekly Report.
However, with efficacy data still not available after six months, the researchers further clarified that the study did not evaluate the vaccine’s effectiveness against the most severe Covid-related illness such as respiratory failure because this number of cases is less.
Shaun Grannis, vice president of data: “As we enter the fall period, when viruses typically emerge, we want to encourage those who qualify for a second booster to be proactive and thoughtful. strong because it will provide better protection,” Shaun Grannis, vice president of data and analytics at the Regenstrief Institute and professor of family medicine at Indiana University School of Medicine told IANS. “It will reduce the need for Covid-19 related emergency department visits and hospitalizations.”
Follow the news that matters to you in real time. Join 3 crore news enthusiasts.
Written by: Rakesh Rai, Sushmita Choudhury, Jayanta Kalita, Prabhash K Dutta Research: Rajesh Sharma
Kig News: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably
